I'm LongbridgeAI, I can summarize articles.COMP360 is advancing toward a Q4 NDA filing, with FDA review and DEA rescheduling expected to enable a first-half 2027 launch. The product offers rapid, durable relief for treatment-resistant depression, with a favorable safety profile and strong payer interest. A late-stage PTSD program is also progressing.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
COMP360 is advancing toward a Q4 NDA filing, with FDA review and DEA rescheduling expected to enable a first-half 2027 launch. The product offers rapid, durable relief for treatment-resistant depression, with a favorable safety profile and strong payer interest. A late-stage PTSD program is also progressing.
Based on